Pharmaceutical

Armodafinil

(R)-2-(Diphenylmethylsulfinyl)acetamide

Evidence TierAWADA PROHIBITED

tuneTypical Dose

150 mg

watchEffect Window

Peaks within 2 hours. Half-life is approximately 15 hours.

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

Armodafinil is the R-enantiomer of modafinil and a prescription wakefulness agent. It treats excessive sleepiness disorders and supports sustained alertness during the day.

Clinical trials show improved wakefulness and reduced daytime sleepiness in narcolepsy, shift work disorder, and sleep apnea-related sleepiness. Cognitive benefits are most apparent under sleep deprivation, improving vigilance and reaction time. Minority studies examine fatigue in neurologic disease and depression, with variable results depending on underlying cause and baseline sleepiness.

R-enantiomer of modafinil. Weak atypical dopamine reuptake inhibitor that elevates hypothalamic histamine and orexin. Longer half-life (~15h) than racemic modafinil (~12h).

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reverses cognitive decline and fatigue from sleep deprivation with longer duration than modafinil
  • Highly effective treatment for narcolepsy and shift-work sleep disorder

Secondary Outcomes

  • Improved sustained attention in healthy adults (off-label)
  • Better afternoon alertness maintenance vs racemic modafinil

Safety

Contraindications and Interactions

Contraindications

  • Severe hepatic impairment
  • History of Stevens-Johnson Syndrome
  • Severe cardiac conditions (LVH, mitral valve prolapse)
  • History of psychosis or mania

Side effects

  • Headache
  • Nausea
  • Dizziness
  • Insomnia
  • Anxiety
  • Stevens-Johnson Syndrome (very rare, potentially fatal)

Interactions

  • Hormonal contraceptives (reduced efficacy via CYP3A4 induction)
  • Warfarin (altered INR)
  • Cyclosporine (reduced levels)
  • High-dose caffeine (additive stimulation)

Avoid if

  • History of psychosis or mania
  • Severe anxiety disorders
  • Unstable cardiovascular disease
  • Pregnancy
  • Lactation

Evidence

Study-level References

armodafinil-SRC-001RCT
Sourceopen_in_new

Czeisler CA, et al. "Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study." Mayo Clin Proc. 2009.

Population: Patients with shift work disorder

Key findings: Armodafinil 150 mg significantly improved wakefulness, overall clinical condition, and long-term memory in patients with excessive sleepiness associated with shift work disorder.

Paper content

Armodafinil 150 mg significantly improved wakefulness, overall clinical condition, and long-term memory in patients with excessive sleepiness associated with shift work disorder.

armodafinil-SRC-002Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Batista Joao R, Pacheco-Barrios N, Leite M, et al. Modafinil/armodafinil for excessive daytime sleepiness after traumatic brain injury: a systematic review and meta-analysis. Brain Inj. 2025;39(11):933-941. doi:10.1080/02699052.2025.2502424. PMID:40388311.

Population: Post-traumatic brain injury patients with excessive daytime sleepiness.

Dose protocol: Modafinil 100-400 mg or armodafinil 150-250 mg versus placebo across 3 RCTs.

Key findings: Meta-analysis of 158 TBI patients found modafinil/armodafinil reduced Epworth Sleepiness Scale scores (MD -1.65) but increased insomnia risk.

Notes: Small pooled sample. TBI population may differ from primary sleep disorder populations.

Paper content

This systematic review and meta-analysis pooled three RCTs (158 patients) evaluating modafinil or armodafinil for excessive daytime sleepiness following traumatic brain injury. Treatment produced a modest but significant reduction in Epworth Sleepiness Scale scores compared to placebo (MD -1.65). However, the risk of insomnia was higher in the active treatment group. The authors concluded that modafinil and armodafinil effectively improved EDS after TBI, though insomnia should be monitored.

armodafinil-SRC-003Systematic review and network meta-analysis of randomized controlled trials.
Sourceopen_in_new

Tanayapong P, Tantrakul V, Liamsombut S, et al. Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure. CNS Drugs. 2025;39(6):527-544. doi:10.1007/s40263-025-01175-7. PMID:40208562.

Population: Adults 18 years or older with obstructive sleep apnea on CPAP experiencing residual excessive sleepiness (ESS 10 or above).

Dose protocol: Armodafinil 150-250 mg/day among four wake-promoting agents compared across 14 RCTs.

Key findings: Network meta-analysis of 2,969 OSA patients confirmed armodafinil effectiveness for residual sleepiness. Solriamfetol ranked highest overall, but all agents outperformed placebo.

Notes: Positions armodafinil within the broader class of wake-promoting agents for OSA.

Paper content

This network meta-analysis pooled 14 RCTs (2,969 patients) comparing four wake-promoting agents for residual sleepiness in CPAP-treated obstructive sleep apnea. All agents, including armodafinil, significantly improved subjective and objective wakefulness measures versus placebo with low rates of serious adverse events. Solriamfetol ranked highest for efficacy on both ESS and MWT endpoints. The analysis confirms that armodafinil is an effective option for residual OSA-related sleepiness within a broader class of wake-promoting agents.

Guides

Setup

Help